Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 72 clinical trials
featured
A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

  • 612 views
  • 08 Nov, 2020
  • 1 location
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

The purpose of study is to evaluate if the addition of GSK3359609 to pembrolizumab as first-line treatment improves the efficacy of pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma/cancer (HNSCC). This is a randomized, double-blind, adaptive Phase II/III study comparing a combination of GSK3359609 …

measurable disease
carcinoma
primary tumor
squamous cell carcinoma
gsk3359609
  • 6 views
  • 01 May, 2021
  • 200 locations
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

the combination of GSK3359609 with pembrolizumab and 5FU-platinum chemotherapy to placebo in combination with pembrolizumab and 5FU-platinum chemotherapy in participants with recurrent or metastatic

measurable disease
carboplatin
carcinoma
primary tumor
squamous cell carcinoma
  • 0 views
  • 13 May, 2021
  • 97 locations
A Study to Determine the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

  • 22 views
  • 27 Jan, 2021
  • 42 locations
Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma

improving significantly the overall survival of patients notably anti-HER molecules. In inoperable recurrent and/or metastatic HNSCC, the best treatment is based on an anti-Human Epidermal Growth Factor

  • 1 views
  • 08 Nov, 2020
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent or metastatic squamous cell carcinoma of head and neck

  • 0 views
  • 10 May, 2021
  • 1 location
A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

This study is a Phase Ib/II, open-label, multicenter clinical trial. Here, the Study Phase Ib is mainly to evaluate safety of Toripalimab + Cetuximab in treatment of relapsed or metastatic HNSCC

  • 0 views
  • 30 Apr, 2021
  • 1 location
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

This is a single arm Phase II study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who are previously treated with a platinum based regimen or with an

  • 42 views
  • 15 May, 2021
  • 1 location
ROMAN: A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

in patients who have been diagnosed with locally advanced, non-metastatic squamous cell carcinoma of the head and neck.

carcinoma
squamous cell carcinoma
intensity-modulated radiation therapy
mucositis
metastatic squamous cell carcinoma
  • 109 views
  • 24 Mar, 2021
  • 115 locations
Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia

This research study is studying an immunotherapy drug, as a possible treatment for oral proliferative verrucous leukoplakia (OPVL).

  • 0 views
  • 25 Jan, 2021